EUVIMEDEUVIMED entdecken
Open Access

In Vitro Synergistic Effects of Omadacycline with Other Antimicrobial Agents against Mycobacterium abscessus

Keiji Fujiwara iD, Akio Aono iD, Takahiro Asami, Kozo Morimoto iD, Keisuke Kamada, Yuta Morishige iD, Yuriko Igarashi iD, Kinuyo Chikamatsu, Yoshiro Murase iD, Hiroyuki Yamada iD, Akiko Takaki, Satoshi Mitarai iD

Antimicrobial Agents and Chemotherapy · 2023

DOI: 10.1128/aac.01579-22 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2023. Verfasst von Keiji Fujiwara und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Mycobacterium Reference and Research, Research Institute of Tuberculosis, Japan Anti-Tuberculosis Association, Tokyo, Japan. Hauptthemen laut MEDLINE: Mycobacterium abscessus, Mycobacterium Infections, Nontuberculous, Anti-Infective Agents, Mycobacterium. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Japan Agency for Medical Research and Development.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The clinical importance of Mycobacterium abscessus species (MABS) infections has been increasing. However, the standard treatment regimens recommended in the current guidelines often result in unfavorable outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mycobacterium abscessusMycobacterium Infections, NontuberculousAnti-Infective AgentsMycobacteriumHumansAnti-Bacterial AgentsClarithromycinAmikacinRifabutinTetracyclinesMicrobial Sensitivity Tests

Stichwörter der Autor:innen

Mycobacterium abscessuscheckerboard methodnontuberculous mycobacteriaomadacyclinesynergy

Substanzen

omadacyclineAnti-Bacterial AgentsClarithromycinAmikacinAnti-Infective AgentsRifabutinTetracyclines

Autor:innen und Institutionen

  • Department of Mycobacterium Reference and Research, Research Institute of Tuberculosis, Japan Anti-Tuberculosis Association, Tokyo, Japan.
  • Respiratory Disease Center, Fukujuji Hospital, Japan Anti-Tuberculosis Association, Tokyo, Japan.
  • Department of Basic Mycobacteriosis, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
  • Department of Clinical Mycobacteriosis, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
  • Division of Clinical Research, Fukujuji Hospital, Japan Anti-Tuberculosis Association, Tokyo, Japan.

ORCID-Profile: Keiji Fujiwara, Akio Aono, Kozo Morimoto, Yuta Morishige, Yuriko Igarashi, Yoshiro Murase, Hiroyuki Yamada, Satoshi Mitarai

Förderung

  • Japan Agency for Medical Research and Development

Zitieren

APA

Fujiwara, K., Aono, A., Asami, T., Morimoto, K., Kamada, K., Morishige, Y., Igarashi, Y., Chikamatsu, K., Murase, Y., Yamada, H., Takaki, A., & Mitarai, S. (2023). In Vitro Synergistic Effects of Omadacycline with Other Antimicrobial Agents against Mycobacterium abscessus. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.01579-22

Vancouver

Fujiwara K, Aono A, Asami T, Morimoto K, Kamada K, Morishige Y, et al. In Vitro Synergistic Effects of Omadacycline with Other Antimicrobial Agents against Mycobacterium abscessus. Antimicrobial Agents and Chemotherapy. 2023. doi:10.1128/aac.01579-22

BibTeX
@article{Fujiwara2023,
  author = {Fujiwara, Keiji and Aono, Akio and Asami, Takahiro and Morimoto, Kozo and Kamada, Keisuke and Morishige, Yuta and Igarashi, Yuriko and Chikamatsu, Kinuyo and Murase, Yoshiro and Yamada, Hiroyuki and Takaki, Akiko and Mitarai, Satoshi},
  title = {In Vitro Synergistic Effects of Omadacycline with Other Antimicrobial Agents against Mycobacterium abscessus},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2023},
  doi = {10.1128/aac.01579-22}
}
Kostenlos starten →